1282 related articles for article (PubMed ID: 33251983)
1. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
[TBL] [Abstract][Full Text] [Related]
2. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
Tatar G; Salmanli M; Dogru Y; Tuzuner T
J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547
[TBL] [Abstract][Full Text] [Related]
4. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
5. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
7. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
[TBL] [Abstract][Full Text] [Related]
8.
Philippsen GS; Seixas FAV
J Biomol Struct Dyn; 2024 Aug; 42(12):6440-6447. PubMed ID: 37424215
[TBL] [Abstract][Full Text] [Related]
9.
Kumar B; Parasuraman P; Murthy TPK; Murahari M; Chandramohan V
J Biomol Struct Dyn; 2022 Oct; 40(17):7796-7814. PubMed ID: 33759690
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive in silico screening of flavonoids against SARS-CoV-2 main protease.
Moezzi MS
J Biomol Struct Dyn; 2023 Nov; 41(19):9448-9461. PubMed ID: 36342071
[TBL] [Abstract][Full Text] [Related]
11. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
12. Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease.
Gogoi N; Chowdhury P; Goswami AK; Das A; Chetia D; Gogoi B
Mol Divers; 2021 Aug; 25(3):1745-1759. PubMed ID: 33236176
[TBL] [Abstract][Full Text] [Related]
13. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential SARS-CoV-2 M
Sobhia ME; Ghosh K; Sivangula S; Kumar S; Singh H
J Biomol Struct Dyn; 2022 Jul; 40(11):5079-5089. PubMed ID: 33413032
[TBL] [Abstract][Full Text] [Related]
15. Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study.
Kumar P; Bhardwaj T; Kumar A; Gehi BR; Kapuganti SK; Garg N; Nath G; Giri R
J Biomol Struct Dyn; 2022 Apr; 40(7):3170-3184. PubMed ID: 33179586
[TBL] [Abstract][Full Text] [Related]
16. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
Yuda GPWC; Hanif N; Hermawan A
Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
[TBL] [Abstract][Full Text] [Related]
17. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
18. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
19.
Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease.
Garg A; Goel N; Abhinav N; Varma T; Achari A; Bhattacharjee P; Kamal IM; Chakrabarti S; Ravichandiran V; Reddy AM; Gupta S; Jaisankar P
J Biomol Struct Dyn; 2023 Mar; 41(5):2033-2045. PubMed ID: 35043750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
